ALGS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aligos Therapeutics Inc (ALGS) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While there are some positive developments in the pipeline and hedge fund interest, the company's financial performance is weak, and the technical indicators suggest a bearish trend. Additionally, there are no strong proprietary trading signals or immediate catalysts to justify a buy decision now.
The technical indicators show a bearish trend with the stock trading below its 200-day, 20-day, and 5-day moving averages. RSI is neutral at 35.533, and MACD is slightly positive but contracting. The stock is near its support level of 6.47, with resistance at 7.379. Overall, the technicals do not suggest a strong entry point.
Hedge funds are increasing their positions, with a 162.30% increase in buying over the last quarter.
Promising developments in the drug pipeline, including ALG-055009 for weight loss and Pevifoscorvir sodium for chronic hepatitis B treatment.
Improved Q4 EPS (-$1.
beat expectations by $0.12, indicating progress in cost management and operational efficiency.
Financial performance remains weak, with significant YoY declines in revenue (-73.13%), net income (-75.80%), EPS (-85.40%), and gross margin (-100%).
The stock price has been volatile, with a regular market change of -2.92% and a post-market drop of -4.37%.
No recent congress trading data or strong insider activity to indicate confidence from influential figures.
For Q4 2025, Aligos reported a revenue drop of 73.13% YoY to $169,000 and a net loss of $19.9 million. EPS dropped 85.40% YoY to -$1.91. Gross margin fell to 0%, reflecting significant challenges in profitability. However, the company has $77.8 million in cash, sufficient to fund operations into Q3 2026.
UBS analyst Michael Yee initiated coverage with a Buy rating and a $20 price target, citing improving biotech fundamentals and potential for strong performance in 2026. However, ALGS was not highlighted as a top pick among the analyst's recommendations, which included other biotech companies with stronger catalysts and broader pipelines.
